In general, ROR2 seems to have tumor suppressive effects particularly in tumors driven by canonical WNT signaling (e.g., colorectal, prostate, or endometrial cancer), whereas it acts rather as an oncogene in tumors with predominantly active non-canonical WNT signaling (e.g., melanoma, breast cancer). Here, ROR2 is linked to melanoma.